Veracyte Inc (VCYT) Stock Price, Quote & News

Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 243 6300

Fax: 650 243 6388

Website: www.veracyte.com

Address:

6000 Shoreline Court, Suite 300, South San Francisco, United States

PhishTourFunds Dec. 30 at 3:38 AM

$VCYT Pullback from $50 mostly complete (weekly chart has several “air gaps”) and accumulation well underway

0 · Reply

EfficiencyExpert Dec. 26 at 10:12 AM

$VCYT Macro trends are relevant, yet internal execution remains the decisive catalyst. Sequential performance needs to stabilize convincingly. Momentum stabilizes only when delivery becomes predictable. The outlook strengthens only as evidence accumulates.

0 · Reply

ZacksResearch Dec. 23 at 7:37 PM

$VCYT's Afirma is outperforming, but is macro pressure a threat? 🤔 📈 Afirma's 13% volume growth and Decipher's 14th consecutive quarter of >25% YoY growth highlight strong diagnostics demand. ⚠️ Macro challenges led to an 11.6% rise in total cost of revenues, impacting growth. Discover the full story on VCYT here 👉 https://www.zacks.com/stock/news/2808193/is-this-the-right-time-to-add-veracyte-stock-to-your-portfolio?cid=sm-stocktwits-2-2808193-body-26098&ADID=SYND_STOCKTWITS_TWEET_2_2808193_BODY_26098

0 · Reply

ZacksResearch Dec. 23 at 6:37 PM

Is $VCYT finally a buy — or a value trap in disguise? ⚖️ Afirma and Decipher are driving strong test volume growth and the company sports a debt-free balance sheet, but rising macro costs and expenses are clearly tempering the outlook. Get the full risk/reward breakdown before making a move 👉 https://www.zacks.com/stock/news/2808193/is-this-the-right-time-to-add-veracyte-stock-to-your-portfolio?cid=sm-stocktwits-2-2808193-teaser-26097&ADID=SYND_STOCKTWITS_TWEET_2_2808193_TEASER_26097

0 · Reply

PhishTourFunds Dec. 22 at 12:55 PM

$VCYT 🔥

0 · Reply

Estimize Dec. 18 at 12:09 PM

Wall St is expecting 0.39 EPS for $VCYT Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/vcyt?chart=historical&metric_name=eps&utm_co

0 · Reply

BillionerOfKing Dec. 10 at 8:11 PM

$VCYT Current Stock Price: $43.12 Contracts to trade: $45 VCYT Dec 19 2025 Call Entry: $0.40 Exit: $0.76 ROI: 89% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Estimize Dec. 2 at 9:00 PM

Wall St is expecting 0.39 EPS for $VCYT Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/vcyt?chart=historical&metric_name=eps&utm_co

0 · Reply

JarvisFlow Dec. 2 at 6:02 PM

Morgan Stanley has updated their rating for Veracyte ( $VCYT ) to Underweight with a price target of 48.

0 · Reply

SilverEagle Dec. 2 at 2:05 PM

$VCYT let it ride

0 · Reply

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Nov 6, 2025, 8:30 AM EST - 2 months ago

Veracyte to Participate in Upcoming Investor Conferences

Nov 4, 2025, 11:46 PM EST - 2 months ago

Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 2 months ago

Veracyte Announces Third Quarter 2025 Financial Results

Nov 3, 2025, 4:15 PM EST - 2 months ago

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Oct 15, 2025, 5:31 PM EDT - 3 months ago

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Sep 28, 2025, 4:00 PM EDT - 3 months ago

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Sep 24, 2025, 9:00 AM EDT - 3 months ago

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Sep 9, 2025, 10:31 PM EDT - 4 months ago

Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 9:00 AM EDT - 4 months ago

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Aug 29, 2025, 8:30 AM EDT - 4 months ago

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 27, 2025, 11:25 AM EDT - 4 months ago

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Aug 26, 2025, 10:18 AM EDT - 4 months ago

Veracyte: Q2 Earnings Brings My Position Out Of Mothballs

Aug 26, 2025, 8:30 AM EDT - 4 months ago

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Aug 7, 2025, 2:20 AM EDT - 5 months ago

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Veracyte Announces Second Quarter 2025 Financial Results

Jul 17, 2025, 5:30 PM EDT - 6 months ago

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Jul 8, 2025, 4:05 PM EDT - 6 months ago

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

May 28, 2025, 4:05 PM EDT - 8 months ago

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

May 8, 2025, 12:49 AM EDT - 8 months ago

Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 8 months ago

Veracyte Announces First Quarter 2025 Financial Results

Apr 25, 2025, 7:00 AM EDT - 9 months ago

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Apr 22, 2025, 9:00 AM EDT - 9 months ago

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Apr 21, 2025, 4:05 PM EDT - 9 months ago

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

Mar 25, 2025, 4:05 PM EDT - 10 months ago

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Mar 19, 2025, 5:00 PM EDT - 10 months ago

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Feb 25, 2025, 10:32 AM EST - 11 months ago

Solid Growth, Soft Outlook: Why I'm Holding On Veracyte

Feb 25, 2025, 10:16 AM EST - 11 months ago

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Feb 24, 2025, 10:53 PM EST - 11 months ago

Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 4:05 PM EST - 11 months ago

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 14, 2025, 8:30 AM EST - 11 months ago

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Feb 11, 2025, 8:30 AM EST - 11 months ago

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

Feb 5, 2025, 8:30 AM EST - 1 year ago

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Feb 4, 2025, 4:30 PM EST - 1 year ago

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

Dec 5, 2024, 4:05 PM EST - 1 year ago

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Nov 6, 2024, 10:49 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 1 year ago

Veracyte Announces Third Quarter 2024 Financial Results

Oct 16, 2024, 6:43 PM EDT - 1 year ago

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

Sep 15, 2024, 8:45 AM EDT - 1 year ago

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Aug 26, 2024, 5:30 PM EDT - 1 year ago

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 9:00 AM EDT - 1 year ago

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Aug 7, 2024, 2:08 PM EDT - 1 year ago

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Aug 6, 2024, 10:17 PM EDT - 1 year ago

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Second Quarter 2024 Financial Results

Jul 17, 2024, 5:00 PM EDT - 1 year ago

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

May 22, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

May 7, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 1 year ago

14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

PhishTourFunds Dec. 30 at 3:38 AM

$VCYT Pullback from $50 mostly complete (weekly chart has several “air gaps”) and accumulation well underway

0 · Reply

EfficiencyExpert Dec. 26 at 10:12 AM

0 · Reply

ZacksResearch Dec. 23 at 7:37 PM

0 · Reply

ZacksResearch Dec. 23 at 6:37 PM

0 · Reply

PhishTourFunds Dec. 22 at 12:55 PM

$VCYT 🔥

0 · Reply

Estimize Dec. 18 at 12:09 PM

Wall St is expecting 0.39 EPS for $VCYT Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/vcyt?chart=historical&metric_name=eps&utm_co

0 · Reply

BillionerOfKing Dec. 10 at 8:11 PM

0 · Reply

Estimize Dec. 2 at 9:00 PM

Wall St is expecting 0.39 EPS for $VCYT Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/vcyt?chart=historical&metric_name=eps&utm_co

0 · Reply

JarvisFlow Dec. 2 at 6:02 PM

Morgan Stanley has updated their rating for Veracyte ( $VCYT ) to Underweight with a price target of 48.

0 · Reply

SilverEagle Dec. 2 at 2:05 PM

$VCYT let it ride

0 · Reply

BEATOFtheMARKET Dec. 2 at 10:22 AM

$VCR $VCYT $VEA $VEEV $VEL

0 · Reply

PhishTourFunds Nov. 24 at 5:40 PM

$VCYT Back at it 🔥

0 · Reply

BEATOFtheMARKET Nov. 24 at 1:51 PM

🔥 $VCR $VCYT $VEA $VEEV $VEL

0 · Reply

VincM Nov. 20 at 7:32 PM

$VCYT wants higher

0 · Reply

VincM Nov. 20 at 6:20 PM

$VCYT trying to break up

0 · Reply

BEATOFtheMARKET Nov. 17 at 3:19 PM

$VCYT $VEA $VECO $VEL $VENU

0 · Reply

BEATOFtheMARKET Nov. 11 at 9:14 PM

11/07 to 11/21 $VCYT $VCEL $VB $VAL $UYG

0 · Reply

JarvisFlow Nov. 11 at 4:59 PM

Morgan Stanley has adjusted their stance on Veracyte ( $VCYT ), setting the rating to Underweight with a target price of 28 → 40.

0 · Reply

ZacksResearch Nov. 11 at 1:24 PM

$VCYT just crushed Q3 earnings — why this stock is soaring! 🚀 📈 EPS jumped 54.5% from the year-ago period, beating estimates by 59.4% 💰 Q3 revenue up 13.8% year over year, outpacing forecasts by 5.5% 🔝 Shares soared 27.5% post-earnings Find out what’s driving this breakout 👉 https://www.zacks.com/stock/news/2789079/vcyt-stock-gains-on-q3-earnings-and-revenue-beat-25-view-up?cid=sm-stocktwits-2-2789079-body-20394&ADID=SYND_STOCKTWITS_TWEET_2_2789079_BODY_20394

0 · Reply

ZacksResearch Nov. 11 at 12:24 PM

$VCYT surges after crushing Q3 expectations — is this just the start? 🚀 Earnings and revenue both beat estimates, fueled by strong growth in Decipher and Afirma test volumes. Full breakdown of Veracyte’s Q3 momentum and upgraded 2025 outlook here 👉 https://www.zacks.com/stock/news/2789079/vcyt-stock-gains-on-q3-earnings-and-revenue-beat-25-view-up?cid=sm-stocktwits-2-2789079-teaser-20393&ADID=SYND_STOCKTWITS_TWEET_2_2789079_TEASER_20393

0 · Reply

HodlMaBeer Nov. 6 at 1:42 PM

$VCYT decent position in wife's name

0 · Reply

DanaBlack Nov. 6 at 4:10 AM

$VCYT overnight

0 · Reply

Market Cap	3.44B
Revenue (ttm)	445.76M
Net Income (ttm)	24.14M
EPS (ttm)	N/A
PE Ratio	40.64
Forward PE	38.07
Profit Margin	5.42%
Debt to Equity Ratio	0.00

Volume	1,208,100
Avg Vol	926,720
Day's Range	N/A - N/A
Shares Out	79.05M
Stochastic %K	11%
Beta	1.88
Analysts	Strong Sell
Price Target	$47.89